Cannabis and autism spectrum disorder
In autism spectrum disorder with severe behavioural symptoms or refractory epilepsy, CBD-rich preparations show improvements in aggression, sleep and seizures in open studies (Aran 2019, Barchel 2019; n>150). RCT evidence remains limited. Only under specialist supervision; in Switzerland, medical prescription is possible (FOPH exceptional authorisation no longer required since 2022).
TL;DR
- Aran 2019 (n=60): CBD:THC 20:1 → improvement in 61%.
- Aran 2021 RCT (n=150): whole-plant CBD better than pure CBD.
- Dosing: CBD ~5 mg/kg/day + THC ≤0.5 mg/kg/day.
- In Switzerland only under medical supervision (Kispi ZH, HUG).
What improves?
Self-injury, rage attacks, hyperactivity and sleep — not core symptoms like social communication.
Neurobiological Foundations and the Endocannabinoid System
The body's own endocannabinoid system plays a fundamental role in regulating neuronal development, synaptic plasticity, and emotional reactivity. Scientific studies suggest that individuals on the autism spectrum may exhibit dysregulation of this system. In particular, the concentration of endogenous cannabinoids such as anandamide appears to follow altered patterns in affected individuals, which can have implications for social information processing and sensory filtering in the brain.
Phytocannabinoids such as CBD and THC target the receptors of this system and can modulate signal transmission. While THC binds directly to the CB1 receptor, CBD acts in a more complex manner, influencing serotonin receptors and the degradation of endogenous neurotransmitters, among other things. This interaction can help dampen neuronal hyperexcitability, which could explain the observed calming effects on anxiety, sensory overload, and motor restlessness in some affected individuals.
- Central role of the endocannabinoid system in neuronal sensory processing
- Evidence of altered endocannabinoid concentrations in autism spectrum disorders
- Modulation of neurotransmitters such as glutamate and GABA by cannabinoids
- Different action profiles of CBD and THC in the central nervous system
Swiss prescribing practice and legal framework
In Switzerland, access to medical cannabis has been facilitated since the amendment of the law in August 2022. Doctors can prescribe corresponding medicinal products directly on prescription without having to obtain a time-consuming exceptional permit from the Federal Office of Public Health (FOPH). For the treatment of symptoms within the scope of an autism spectrum disorder, prescription is usually off-label, often initiated by specialised centres such as university children's hospitals or psychiatric services.
When selecting products, the strict legal limit values must be taken into account. Preparations with a total THC content of less than one percent do not fall under the Narcotics Act, while THC-dominant formulations are subject to stricter controls. Furthermore, the legal situation regarding road traffic is extremely strict: since a THC limit of 1.5 micrograms per litre of blood applies in Switzerland, the use of THC-containing medications in practice usually leads directly to unfitness to drive.
- Direct medical prescribability of medical cannabis since August 2022
- Demarcation from narcotics via the legal limit of less than one percent total THC
- Strict zero-tolerance practice in Swiss road traffic with a limit of 1.5 µg/L in blood
- Individual clarification of the guarantee of payment by the health insurance provider before starting therapy
Differentiated perspective: accompanying symptoms versus core symptoms
When supporting autism therapeutically with cannabinoids, a realistic expectation is crucial. Clinical evidence suggests that cannabinoids primarily influence the accompanying symptoms and not the core symptoms of autism spectrum disorder. While social communication difficulties and repetitive behaviours are hardly directly altered by the medication, observational studies often show clear improvements in comorbid burdens such as sleep disorders, severe aggression, or self-harming behaviour.
This relief of secondary symptoms can significantly increase the quality of life of those affected and their families. Nevertheless, professional associations urge caution, as controlled long-term studies on safety and efficacy, especially in children, remain rare. Close medical supervision is essential to detect adverse effects such as fatigue, changes in appetite, or interactions with other medications at an early stage and to adjust the dosage individually.
- Focus of the effect on accompanying symptoms such as sleep disorders, aggression, and hyperactivity
- No direct cure or fundamental change in the core autistic symptoms
- Necessity of individual and close dose titration under professional supervision
- Consideration of potential side effects and interactions with other psychotropic drugs
The concrete process of initiating therapy in Switzerland
The path to a cannabis-supported adjunctive therapy for autism in Switzerland always begins with a sound psychiatric or pediatric diagnosis. Since this is an off-label use, consulting specialized medical specialists or university centers is advisable. After the initial assessment, an individual treatment plan is created. Dosage finding follows the "low and slow" principle, with the dose being increased in the smallest steps until the desired effect on the accompanying symptoms is achieved. This process requires patience and precise documentation by relatives.
During the titration phase, regular follow-up appointments are mandatory to monitor tolerability. This involves not only recording behavioral changes but also checking physical parameters such as liver values. Swiss doctors work closely with specialized pharmacies that custom-prepare the magistral formulations. This close supervision ensures that the quality of the preparation remains constant and that immediate action can be taken in the event of adverse effects. Self-medication without medical supervision is strictly discouraged due to the complex dosing.
- Initial assessment and confirmation of diagnosis by qualified specialists in Switzerland
- Creation of an individual treatment plan with gradual dose adjustment (titration)
- Regular follow-up examinations to monitor efficacy and physical tolerability
- Preparation of standardized magistral formulations by specialized Swiss pharmacies
Risks of interactions and the role of Swiss specialist agencies
The use of cannabinoids in autism spectrum disorders is not without risks, especially if other medications are already being taken. Many autistic people receive antiepileptics, antidepressants, or neuroleptics to treat co-occurring conditions. Since both CBD and THC are metabolized via the liver's enzyme systems, dangerous interactions can occur. Cannabinoids can unpredictably raise or lower the levels of other medications in the blood. This increases the risk of severe side effects or significantly reduces the therapeutic efficacy of the baseline medication.
In case of suspected overdose or unexpected interactions, the Swiss emergency number of Tox Info Suisse (145) offers fast and competent assistance around the clock. In addition, Swissmedic, as the Swiss Agency for Therapeutic Products, monitors the safety of preparations on the market. Doctors are legally required to report serious adverse drug reactions to Swissmedic. These state control mechanisms ensure a high level of patient safety that can never be guaranteed when using products from the unregulated grey market.
- Increased risk of interactions with antiepileptics, neuroleptics, and antidepressants
- Influence on drug metabolism in the liver through the blockade of cytochrome P450 enzymes
- Around-the-clock emergency consultation in case of suspected poisoning via Tox Info Suisse (telephone 145)
- Mandatory reporting of serious adverse effects to the supervisory authority Swissmedic
Distinction from the unregulated market and CBD retail outlets
For parents and those affected, going to an ordinary CBD shop or buying over-the-counter CBD oils online may seem like an easy way out. In Switzerland, products with a total THC content of less than one percent are legally available, but they are subject to food or chemical legislation and not to the strict guidelines for medicinal products. The quality, actual active ingredient content and purity of these over-the-counter products often vary significantly. For medical therapy where precise dosing is essential, such lifestyle products are completely unsuitable.
Medical cannabis preparations, on the other hand, must meet the strict requirements of the pharmacopoeia. They are standardised, free from contaminants such as pesticides, heavy metals or solvents, and have an exactly defined active ingredient content. Only in this way can a reproducible dosage and thus a safe therapy be guaranteed. Furthermore, over-the-counter products completely lack medical advice and the crucial assessment of contraindications. Purchasing them from official Swiss pharmacies with a medical prescription protects patients from health risks.
- Risk of quality fluctuations and inaccurate active ingredient specifications in over-the-counter CBD products
- Lack of purity certificates regarding heavy metals and pesticides in the lifestyle market
- Necessity of medical standardisation for precise and reproducible dosing in everyday life
- Safe sourcing exclusively through Swiss pharmacies as part of medical supervision
Practical testing in everyday life and cantonal specificities in the school system
Integrating cannabis therapy into the everyday lives of autistic children and adolescents presents families with practical challenges, particularly in the school environment. Administering medical extracts during school hours requires clear agreement with the school administration and teachers. Since the administration of the school system in Switzerland is the responsibility of the cantons, there are no uniform federal rules for administering medication in schools. It is advisable to involve the cantonal school doctor or the school medical service at an early stage in order to reach a legally secure agreement.
When transporting and carrying the medication, parents should always carry a copy of the medical prescription or a corresponding treatment card. This is particularly important for preparations with a THC content that is subject to the Narcotics Act. Although a fixed penalty of 100 francs is stipulated for adults in possession of small quantities for personal consumption, different rules apply to medically prescribed preparations. Transparent communication with everyone involved in the child's social environment prevents misunderstandings and ensures the necessary safety in everyday life.
- Cantonal differences in the guidelines for administering medication in Swiss schools
- Necessity of written agreements with school administrations and teachers for administration
- Carrying copies of prescriptions or medical certificates to prove the medical indication
- Involvement of the cantonal school medical service to clarify legal and practical questions
FAQ
Is this approved in Switzerland?
No, off-label via exceptional authorisation. Considered case-by-case at centres like Kinderspital Zürich.
What role does the THC content play in the treatment of autism in Switzerland?
In medical practice for autism spectrum disorders, CBD-dominant preparations are primarily used. The THC content is usually kept very low to avoid psychoactive effects. In Switzerland, products with a total THC content of less than one percent are not subject to the Narcotics Act. However, higher-dose THC preparations can be prescribed by a doctor if clinically indicated. In doing so, the strict legal requirements regarding road traffic and storage must always be observed.
Do Swiss health insurance companies cover the costs of cannabis therapy for autism?
Mandatory health insurance does not automatically cover the costs of medical cannabis. Since the treatment of autism symptoms with cannabis is generally conducted on an off-label basis, the treating physician must submit a request for cost assumption to the health insurer before starting therapy. The decision on cost coverage is always made on a case-by-case basis by the respective insurer's medical advisory service, based on the course of therapy to date and medical necessity.
What risks and side effects must be considered during use?
Although CBD-rich preparations are often well tolerated, side effects such as drowsiness, gastrointestinal complaints, changes in appetite, or mood swings can occur. It is particularly important to consider drug interactions, as cannabinoids can influence the metabolism of other medications in the liver. This frequently affects antiepileptics or neuroleptics, which are sometimes prescribed concomitantly for autism. Regular monitoring of liver values and close coordination with the treating specialist are therefore strongly recommended.
Can my autistic child take medical cannabis at a Swiss school?
Yes, taking it at school is generally possible, but requires a prior written agreement with the school management and the teaching staff. Since the school system in Switzerland is regulated at the cantonal level, there are no federal regulations for the administration of medication. Parents should present a medical certificate confirming the necessity and the exact dosage. Often, the cantonal school medical service helps to find a safe and legally sound solution for the teaching staff.
What happens if my child accidentally takes an overdose of the cannabis preparation?
In case of a suspected overdose, you should immediately call the Swiss emergency number of Tox Info Suisse on 145 or contact a doctor. Typical signs of an overdose with CBD-rich preparations include pronounced fatigue, dizziness, diarrhoea or an altered heart rate. Keep calm and have the packaging of the medication ready so that the specialists can assess the exact concentration of the active substance and give you specific instructions on how to act in the situation.
Why am I not allowed to use cheap CBD oil from the drugstore for my child's therapy?
Over-the-counter CBD oils from drugstores or health food stores are unsuitable for medical therapy because they are not subject to the strict quality and purity standards of the Medicines Act. Their active substance concentration can fluctuate greatly, making precise and constant dosing impossible. In addition, there is a risk of contamination with harmful substances. Only magistral formulations from the pharmacy guarantee the standardisation, freedom from contaminants and medical supervision required for supportive autism therapy.
Does the Swiss zero-tolerance limit in road traffic also apply to adolescents with autism?
Yes, the legal limit of 1.5 micrograms of THC per litre of blood applies without exception to all motorised road users in Switzerland, regardless of age or medical indication. As soon as adolescents drive a moped, a scooter or, later, a car, the detection of THC above this limit leads to unfitness to drive. In the case of therapy with preparations containing THC, the topic of fitness to drive must therefore be discussed at an early stage with the treating physician.